TNFRSF12A and cancer: Tumoral Fn14 has been shown to induce cancer cachexia in several preclinical models, with an antagonistic anti-Fn14 antibody (002 mAb) treatment able to reverse this condition [7], making Fn14 a potential target for treating cancer cachexia.